Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

CAR-T Digest - August 2020

20 June 2024: Tubulis Doses First Patient in Phase I/IIa Trial Investigating ADC Candidate TUB-040 in Ovarian Cancer and Lung Adenocarcinoma

Tubulis has initiated a Phase I/IIa trial (NAPISTAR 1-01, NCT06303505) for its ADC candidate TUB-040 in platinum-resistant high-grade ovarian cancer (PROC) and relapsed/refractory NSCLC, following FDA IND approval
The trial aims to assess TUB-040’s safety, tolerability, pharmacokinetics, and efficacy as a monotherapy through multicenter dosage escalation and optimization studies
TUB-040, based on preclinical research, offers a promising alternative for treating ovarian cancer (OC) and NSCLC by enhancing anti-tumor responses and minimizing non-target toxicity
The first patient has been dosed in the United States, marking a critical milestone in Tubulis’ efforts to improve therapeutic outcomes in OC and NSCLC patients with TUB-040